A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Before showing the documents to Sports Illustrated, Exum tried to use them in a lawsuit against USOC, accusing the organization of racial discrimination and wrongful termination against him and cover-up over the failed tests. the Denver federal Court summarily dismissed his case for lack of evidence. The USOC labelled his case "baseless" as he himself was the one in charge of screening the anti-doping test program of the organization and clarifying that the athletes were cleared according to the rules. Carl Lewis broke his silence on allegations that he was the beneficiary of a drugs cover-up, admitting he had failed tests for banned substances, but claiming he was just one of "hundreds" of American athletes who were allowed to escape bans, concealed by the USOC. Lewis has acknowledged that he failed three tests during the 1988 US Olympic trials, which under international rules at the time should have prevented him from competing in the 1988 Summer Olympics. Former athletes and officials came out against the USOC cover-up. "For so many years I lived it. I knew this was going on, but there's absolutely nothing you can do as an athlete. You have to believe governing bodies are doing what they are supposed to do. And it is obvious they did not," said former American sprinter and 1984 Olympic champion, Evelyn Ashford. Exum's documents revealed that Carl Lewis had tested positive three times at the 1988 Olympics trials for minimum amounts of pseudoephedrine, ephedrine, and phenylpropanolamine, which were banned stimulants. Bronchodilators are also found in cold medication.
== Works cited == Bateman, Sam (2016). "Maritime security governance in the Indian Ocean region". Journal of the Indian Ocean. 12 (1): 5–23. Afghan Opiate Trafficking Through the Southern Route (PDF) (Report). UNODC. 2015. Retrieved 1 May 2020. Impacts of Drug Use on Users and their Families in Afghanistan (PDF) (Report). UNODC. 2014. Retrieved 20 March 2020. Malcolm & Murray, James A. & Linganaden (2017). "Small islands' understanding of Maritime security: the cases of Mauritius and Seychelles". Journal of the Indian Ocean. 13 (2): 234–256. McLaughlin, Rob (2016). "Towards a more effective counter-drugs regime in the Indian Ocean". Journal of the Indian Ocean Region. 12 (1): 24–38. doi:10.1080/19480881.2016.1138710.
==== D. Lymphatic system of the nose ==== The pertinent nasal lymphatic system arises from the superficial mucosa, and drains posteriorly to the retropharyngeal nodes (in back), and anteriorly (in front), either to the upper deep cervical nodes (in the neck), or to the submandibular glands (in the lower jaw), or into both the nodes and the glands of the neck and the jaw.
Sources: en.wikipedia.org
Jackson, A. Y. (1943). Banting as an Artist. Ryerson Press. Shaw, Margaret Mason (1976). Frederick Banting. Fitzhenry & Whiteside. ISBN 978-0-88902-229-4. Stevenson, Lloyd (1946). Sir Frederick Banting. Ryerson Press. Harris, Seale (1946). Banting's miracle; the story of the discoverer of insulin. Lippincott. Walters, Eric (2005). Elixir. Puffin Canada. ISBN 978-0-14-301641-0. Raju, T. N. (1998). "The Nobel Chronicles. 1923: Frederick G Banting (1891–1941), John J R Macleod (1876–1935)". Lancet. 352 (9138): 1482. doi:10.1016/s0140-6736(05)61319-0. PMID 9808029. S2CID 54323266. Hudson, R. P. (1979). "New light on the insulin controversy (Frederick G. Banting and J. J. R. Macleod)". Annals of Internal Medicine. 91 (2): 311. doi:10.7326/0003-4819-91-2-311. PMID 380438. Fletcher, K. (2007). "Sir Frederick Banting homestead sold to developer, family outraged". Canadian Medical Association Journal. 176 (12): 1691–92. doi:10.1503/cmaj.070613. PMC 1877854. PMID 17548378. Shampo, M. A.; Kyle, R. A. (2005). "Frederick Banting – Nobel Laureate for Discovery of Insulin". Mayo Clinic Proceedings. 80 (5): 576. doi:10.4065/80.5.576. PMID 15887423. MacLeod, J. B. A. (2006). "Frederick G. Banting: Giving Prospects for Life from the Past to the New Millennium". Archives of Surgery. 141 (7): 705–07. doi:10.1001/archsurg.141.7.705. PMID 16847245. Elliot, J. C. (2004). "Banting – a Nobel artist". The Medical Journal of Australia. 181 (11–12): 631. doi:10.5694/j.1326-5377.2004.tb06494.x. PMID 15588191. S2CID 10131078. Todhunter, E. N. (1953). "Frederick G.
=== Return to Essendon Football Club (2010–2014) === On 10 November 2010, Thompson signed a lucrative contract to return to Essendon as the senior assistant coach under senior coach James Hird, putting an end to weeks of speculation following his resignation from Geelong. According to football writer and commentator Caroline Wilson's sources, his contract was said to be worth $650,000 per year. He was appointed the senior coach for the 2014 season while James Hird served his suspension, and left the club after Hird returned as senior coach at the end of that year.
However, antiviral resistance is known to develop if mutations to the neuraminidase proteins prevent NAI binding. This was seen in the H257Y mutation, which was responsible for oseltamivir resistance to H1N1 strains in 2009. The inability of NA inhibitors to bind to the virus allowed this strain of virus with the resistance mutation to spread due to natural selection. Furthermore, a study published in 2009 in Nature Biotechnology emphasized the urgent need for augmentation of oseltamivir stockpiles with additional antiviral drugs including zanamivir. This finding was based on a performance evaluation of these drugs supposing the 2009 H1N1 'Swine Flu' neuraminidase (NA) were to acquire the oseltamivir-resistance (His274Tyr) mutation, which is currently widespread in seasonal H1N1 strains.
All mRNA templates used for mRNA display technology have puromycin at their 3' end. As translation proceeds, the ribosome moves along the mRNA template, and once it reaches the 3' end of the template, the fused puromycin will enter ribosome's A site and be incorporated into the nascent peptide. The mRNA-peptide fusion is then released from the ribosome (Figure 1). To synthesize an mRNA-peptide fusion, the fused puromycin is not the only modification to the mRNA template. Oligonucleotides and other spacers need to be incorporated along with the puromycin to provide flexibility and proper length for the puromycin to enter the A site. Ideally, the linker between the 3' end of an mRNA and the puromycin has to be flexible and long enough to allow the puromycin to enter the A site upon translation of the last codon. This enables the efficient production of high-quality, full-length mRNA-peptide fusions. Rihe Liu et al. optimized the 3'-puromycin oligonucleotide spacer. They reported that dA25 (a nucleotide sequence of 25 deoxyadenosine residues) in combination with a Spacer 9 (Glen Research), and dAdCdCP at the 5' terminus worked the best for the fusion reaction. They found that linkers longer than 40 nucleotides and shorter than 16 nucleotides showed greatly reduced efficiency of fusion formation. Also, when the sequence rUrUP was present adjacent to the puromycin, fusion did not form efficiently.
Sources: en.wikipedia.org
=== Stabilization that provides partial support or protection === Structural weakness and damage must be supported in textiles, especially areas such as the top of tapestries and the shoulders of garments
=== Satiety === L cells are enteroendocrine cells, i.e., specialized cells that secrete hormones directly into the circulation. L cells reside in the epithelium of the gastrointestinal tract, particularly the terminal ileum and colon. They are stimulated to secrete PYY (also termed peptide YY) and GLP-1 (also termed glucagon-like peptide-1) by the SC-FAs that accumulate inside the intestines after feeding. L cells express FFAR3 and/or FFAR2. Ffar3 and Ffar2 gene knock out mice show reduced secretions of GLP-1 and PYY. Leptin is a peptide hormone released by adipose tissue that triggers satiety and thereby tends to reduce or stop further food intake and the development of obesity. It also plays a role in female reproductive function, lipolysis (e.g., the breakdown of triglycerides into their component free fatty acids and glycerol), the growth of fetuses, inflammation, and angiogenesis (i.e., the formation of new blood vessels from pre-existing blood vessels). While studies have suggested that the SC-FA-induced activation of FFAR3 leads to the secretion of leptin from the white adipose tissue of intact animals and the fat tissue isolated from human tissues, other studies have suggested that FFAR2 rather than FFAR3 is responsible for the SC-FA-induced release of leptin from fat tissue. A systematic review of the published studies on this issue concluded that SC-FA-induced activation of FFAR3 is likely responsible for the SC-FA-induced release of leptin from cultured fat tissue taken from animals.
For example, if the desired analyte has a high amount of acidity, it would be logical to choose a matrix with a high amount of basicity to avoid competition and facilitate the formation of an ion. The pH of the matrix can also be used to select what sample you want to obtain spectra for. For example, in the case of proteins, a very acidic pH can show very little of the peptide components, but can show very good signal for those components that are larger. If the pH is increased towards a more basic pH, then smaller components become easier to see.
biosynthesis from the sulfur amino acids (e.g., cysteine); active uptake by a taurine transporter; and the extent of its release from cells by a "volume-sensitive leak pathway". Taurine is a major constituent of bile, and can be found in the large intestine. Its concentrations in land plants are low or undetectable, but up to a substantial wet weight has been found in algae.
The enzyme characterised from Azotobacter vinelandii hydrolyses the nucleotide, nicotinamide mononucleotide, to give nicotinate mononucleotide and ammonia. Manufacture of nicotinamide mononucleotide for use as a pharmaceutical drug has been studied and in this context its degradation by nicotinamide-nucleotide amidase is undesirable, so means to down-regulate the enzyme or remove its associated gene have been sought. This enzyme is a hydrolase, one acting on carbon-nitrogen bonds other than peptide bonds, specifically in linear amides. The systematic name of this enzyme class is nicotinamide-D-ribonucleotide amidohydrolase. Other names in use include NMN deamidase, nicotinamide mononucleotide deamidase, and nicotinamide mononucleotide amidohydrolase.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.